Scarica l'app Stockscreener
67.79
2.11%
1.40
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$66.39
Aprire:
$66.3
Volume 24 ore:
1.16M
Relative Volume:
0.51
Capitalizzazione di mercato:
$9.21B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-48.77
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
-3.38%
1M Prestazione:
+16.98%
6M Prestazione:
+301.12%
1 anno Prestazione:
+244.99%
Intervallo 1D:
$65.00
$68.25
Intervallo di 1 settimana:
$65.00
$69.69
Portata 52W:
$9.57
$72.36
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
67.79 | 9.02B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Bernstein raises Arrowhead Pharma stock price target to $35 on obesity data - Investing.com Canada
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Corient Private Wealth LLC Takes Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells $527,100.00 in Stock - MarketBeat
Ferrari Mauro sells $527k in Arrowhead Pharmaceuticals (ARWR) By Investing.com - Investing.com UK
Ferrari Mauro sells $527k in Arrowhead Pharmaceuticals (ARWR) - Investing.com India
Arrowhead Pharmaceuticals Insider Sold Shares Worth $527,100, According to a Recent SEC Filing - marketscreener.com
Arrowhead Pharmaceuticals Executives Conduct Major Stock Transactions - TradingView — Track All Markets
Arrowhead Pharmaceuticals stock slides today as biotech dips; ARWR investors eye January obesity data - ts2.tech
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 3.9%Time to Sell? - MarketBeat
Arrowhead rises as FDA approves lead drug for rare disorder - MSN
These 4 Measures Indicate That Arrowhead Pharmaceuticals (NASDAQ:ARWR) Is Using Debt Reasonably Well - 富途牛牛
Trading the Move, Not the Narrative: (ARWR) Edition - Stock Traders Daily
HBK Sorce Advisory LLC Invests $2.82 Million in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Exchange Traded Concepts LLC Sells 15,265 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Texas Permanent School Fund Corp Buys Shares of 19,104 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Voya Investment Management LLC Has $4.74 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
76,408 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Acquired by HBK Sorce Advisory LLC - MarketBeat
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch - Sahm
Arrowhead Pharma director Waddill sells $566k in stock By Investing.com - Investing.com Australia
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 12,586 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Victoria Vakiener Sells 10,040 Shares - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 10,000 Shares of Stock - MarketBeat
Arrowhead Pharma director Waddill sells $566k in stock - Investing.com
Olukotun of Arrowhead Pharma sells $676k in stock By Investing.com - Investing.com Nigeria
Arrowhead Pharma director Vakiener sells $679k in stock By Investing.com - Investing.com Nigeria
Olukotun of Arrowhead Pharma sells $676k in stock - Investing.com
Arrowhead Pharma CEO Anzalone sells $1.77m in stock By Investing.com - Investing.com UK
Rate Cut: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsPortfolio Gains Summary & Risk Controlled Stock Pick Alerts - moha.gov.vn
First Week of February 2026 Options Trading For Arrowhead Pharmaceuticals (ARWR) - Nasdaq
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events - Business Wire
Arrowhead Pharmaceuticals Insider Sold Shares Worth $5,443,462, According to a Recent SEC Filing - marketscreener.com
Arrowhead Pharmaceuticals, Inc. $ARWR Holdings Boosted by Assenagon Asset Management S.A. - MarketBeat
Christopher Richard Anzalone Sells 85,000 Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Is Down 6.1% After First CNS RNAi Alzheimer’s Trial Dosing – Has The Bull Case Changed? - Sahm
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Trade Ideas & AI Forecast Swing Trade Picks - DonanımHaber
Behavioral Patterns of ARWR and Institutional Flows - news.stocktradersdaily.com
Trading Action: Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsGap Down & Detailed Earnings Play Strategies - moha.gov.vn
Can Arrowhead Pharmaceuticals Inc. stock attract ESG capital inflowsJuly 2025 Movers & AI Powered Trade Plan Recommendations - Улправда
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $10 - GuruFocus
Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch - Investing.com UK
ARWR (Arrowhead Pharmaceuticals) 12-1 Month Momentum % : 84.44% (As of Dec. 17, 2025) - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 54,298 Shares - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 130,000 Shares of Stock - MarketBeat
Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching - ts2.tech
Arrowhead (ARWR) Experiences Notable Decline in Share Price - GuruFocus
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6%What's Next? - MarketBeat
Arrowhead (ARWR) Sees Significant Decline as Stock Drops Over 12% - GuruFocus
Hudson Bay Capital Management LP Purchases 46,870 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arrowhead Pharmaceuticals Inc Azioni (ARWR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer |
Dec 29 '25 |
Option Exercise |
6.15 |
51,726 |
318,115 |
3,857,652 |
| Anzalone Christopher Richard | Chief Executive Officer |
Dec 29 '25 |
Sale |
69.13 |
51,726 |
3,575,575 |
3,805,926 |
| Ferrari Mauro | Director |
Dec 26 '25 |
Sale |
70.00 |
7,530 |
527,100 |
69,053 |
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):